FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2295832768> ?p ?o ?g. }

• W2295832768 abstract "9031 Background: Our team reported at the 42 nd ASCO meeting that continuous, low-dose intravenous (IV) lidocaine is an effective method for pain relief in terminal patients with peritoneal carcinomatosis. Our aim was to explore the mechanism by which abdominal pain of terminally-ill patients with peritoneal carcinomatosis was improved by continuous IV lidocaine. Methods: 48 patients with peritoneal carcinomatosis due to GI (46) and GYN (2) malignancies were administered lidocaine at low-doses (0.4 and/or 0.8mg/kg- h) for >24 hours, because opiates, NSAIDs, and other adjuvants were ineffective in relieving their abdominal pain. Pain (faces rating scale; 0-no pain, 5-worst pain), oral intake, side effects, and activities of daily life were quantified. Two days after beginning lidocaine, ascites was sampled to measure ascitic concentration of lidocaine, tumor markers and cytology. Results: Mean age (±SE) was 60±2. The volume of ascites was estimated to be 2,700±400ml by the ultrasound 5 points methodology. Abdominal symptoms improved in 1.5±0.2days after beginning lidocaine, and the pain scale decreased from 1.9±0.2 to 0.5±0.1; p<0.001; 75% of patients had improvement in pain of whom 78% had complete relief of pain. Oral intake increased from 18% to 49% of baseline (p<0.001), and 67% in those with improvement in pain had an increased volume of oral intake. There were no obvious differences in response to 0.4 and 0.8 mg/kg-h in patients receiving both doses. Serum concentrations of lidocaine at 0.4 and 0.8 mg/kg-h were 1.7±0.2 and 3.2±0.2 μg/ml, respectively; lidocaine concentrations in the ascites were 1.2±0.2 and 2.1±0.2 μg/ml. No patient complained of pain at the time of peritoneal puncture. Side effects included bradycardia of <60 beats per minutes (3 patients). The duration of lidocaine administration was 23±3 days; 43% of patients were able to be discharged home for end-of-life care, with parenteral nutrition and continuation of lidocaine administration or oral mexiletine (300–450 mg/day) for adjuvant analgesia. Conclusions: Lidocaine diffuses into ascites and almost equilibrates with serum concentrations acting as a peritoneal anesthesia which, as a result, controls abdominal pain in patients with peritoneal carcinomatosis. No significant financial relationships to disclose." @default.
• W2295832768 created "2016-06-24" @default.
• W2295832768 creator A5005708432 @default.
• W2295832768 creator A5010352480 @default.
• W2295832768 creator A5010809427 @default.
• W2295832768 creator A5024661044 @default.
• W2295832768 creator A5051780206 @default.
• W2295832768 creator A5076385445 @default.
• W2295832768 creator A5078658966 @default.
• W2295832768 creator A5079381150 @default.
• W2295832768 creator A5087778963 @default.
• W2295832768 date "2007-06-20" @default.
• W2295832768 modified "2023-10-16" @default.
• W2295832768 title "Continuous intravenous lidocaine controls abdominal pain secondary to peritoneal carcinomatosis as a consequence of diffusion into ascites" @default.
• W2295832768 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.9031" @default.
• W2295832768 hasPublicationYear "2007" @default.
• W2295832768 type Work @default.
• W2295832768 sameAs 2295832768 @default.
• W2295832768 citedByCount "0" @default.
• W2295832768 crossrefType "journal-article" @default.
• W2295832768 hasAuthorship W2295832768A5005708432 @default.
• W2295832768 hasAuthorship W2295832768A5010352480 @default.
• W2295832768 hasAuthorship W2295832768A5010809427 @default.
• W2295832768 hasAuthorship W2295832768A5024661044 @default.
• W2295832768 hasAuthorship W2295832768A5051780206 @default.
• W2295832768 hasAuthorship W2295832768A5076385445 @default.
• W2295832768 hasAuthorship W2295832768A5078658966 @default.
• W2295832768 hasAuthorship W2295832768A5079381150 @default.
• W2295832768 hasAuthorship W2295832768A5087778963 @default.
• W2295832768 hasConcept C121608353 @default.
• W2295832768 hasConcept C126322002 @default.
• W2295832768 hasConcept C141071460 @default.
• W2295832768 hasConcept C2780149897 @default.
• W2295832768 hasConcept C2780496750 @default.
• W2295832768 hasConcept C2780955771 @default.
• W2295832768 hasConcept C2991818862 @default.
• W2295832768 hasConcept C42219234 @default.
• W2295832768 hasConcept C526805850 @default.
• W2295832768 hasConcept C71924100 @default.
• W2295832768 hasConceptScore W2295832768C121608353 @default.
• W2295832768 hasConceptScore W2295832768C126322002 @default.
• W2295832768 hasConceptScore W2295832768C141071460 @default.
• W2295832768 hasConceptScore W2295832768C2780149897 @default.
• W2295832768 hasConceptScore W2295832768C2780496750 @default.
• W2295832768 hasConceptScore W2295832768C2780955771 @default.
• W2295832768 hasConceptScore W2295832768C2991818862 @default.
• W2295832768 hasConceptScore W2295832768C42219234 @default.
• W2295832768 hasConceptScore W2295832768C526805850 @default.
• W2295832768 hasConceptScore W2295832768C71924100 @default.
• W2295832768 hasLocation W22958327681 @default.
• W2295832768 hasOpenAccess W2295832768 @default.
• W2295832768 hasPrimaryLocation W22958327681 @default.
• W2295832768 hasRelatedWork W187164829 @default.
• W2295832768 hasRelatedWork W2047967234 @default.
• W2295832768 hasRelatedWork W2295832768 @default.
• W2295832768 hasRelatedWork W2912673055 @default.
• W2295832768 hasRelatedWork W3009514965 @default.
• W2295832768 hasRelatedWork W3198439696 @default.
• W2295832768 hasRelatedWork W4240356544 @default.
• W2295832768 hasRelatedWork W4242623542 @default.
• W2295832768 hasRelatedWork W4244068869 @default.
• W2295832768 hasRelatedWork W216485569 @default.
• W2295832768 isParatext "false" @default.
• W2295832768 isRetracted "false" @default.
• W2295832768 magId "2295832768" @default.
• W2295832768 workType "article" @default.